When activated, microglial cells have the potential not only to secrete typical proinflammatory mediators but also to release the neurotransmitter glutamate in amounts that may promote excitotoxicity. Here, we wished to determine the potential of the Parkinson's disease (PD) protein α-Synuclein (αS) to stimulate glutamate release using cultures of purified microglial cells. We estab- 
| INTRODUCTION
Parkinson disease (PD) is a multifactorial neurodegenerative disorder primarily characterized by a loss of midbrain substantia nigra dopamine (DA) neurons and ensuing motor deficits (Michel, Hirsch, & Hunot, 2016; Mullin & Schapira, 2015) . Neuronal cell loss is probably the result of intrinsic mechanisms that affect neuronal function and Abbreviations: αS, α-Synuclein; αSa, αS aggregates; αSm, αS monomers; APO, Apocynin; BzATP, 2 0 (3 0 )-O-(4-Benzoylbenzoyl)-ATP; DA, dopamine; DAPI, 4 0 ,6-Diamidino-2-PhenyIindole; DMEM, Dulbecco's modified Eagle's medium; DPI, Diphenyleneiodonium; ERG, 2-bromo-α-ergocryptine; FCS, fetal calf serum; FK, forskolin; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; Iba-1, Ionized calcium binding adaptor molecule-1; JNJ, JNJ-47965567 or 2-(Phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl] methyl-3-pyridinecarboxamide; LPS, Lipopolysaccharide; LY, LY294002 or 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride; NOX, NADPH oxidase; PBS, Dulbecco's phosphate buffered saline medium; PD, Parkinson's disease; PEI, polyethyleneimine; PI3K, Phosphoinositide 3-kinase; ROS, reactive oxygen species; Sulfa, sulfasalazine; TEM, Transmission electron microscopy; TLR, Toll-like Receptor; TROL, trolox ultimately neuronal viability. It is believed, however, that neurodegeneration is exacerbated by sustained inflammatory processes that implicate microglial cells (Hirsch et al., 2003; McGeer & McGeer, 2008) , the resident immune cells of the brain (Bohlen et al., 2017; Ginhoux et al., 2010) . Microglial activation in PD may not simply occur as a consequence of neuronal damage as originally thought but also as an intrinsic component of the disease process (Mouton-Liger et al., 2018) .
Microglial cell activation was demonstrated in post-mortem tissue (Hirsch et al., 2003; McGeer & McGeer, 2008) and in living patients diagnosed with PD, using positron emission tomography imaging techniques (Bartels et al. 2010; Ouchi, Yagi, Yokokura, & Sakamoto, 2009 ).
The contribution of inflammatory processes in PD progression is also indirectly supported by epidemiological studies showing that the PD risk is reduced in long-term users of some nonsteroidal antiinflammatory medications (Gagne & Power, 2010; Rees et al., 2011) .
A number of studies suggest that the aggregation process which affects the synaptic protein α-Synuclein (αS), could represent a potential trigger for microglial cell activation (Couch, Alvarez-Erviti, Sibson, Wood, & Anthony, 2011; Lema Tomé et al., 2013; Zhang et al., 2005) .
Microglial activation may result from the presence of pathological αS aggregates that diffuse and propagate in the brain parenchyma of PD patients (Bernis et al., 2015; Dijkstra et al., 2014; Emmanouilidou et al., 2011) to finally form cytoplasmic inclusions, termed Lewy bodies, and abnormal neuritic depositions, termed Lewy neurites (Braak & Del Tredici, 2017) . Consistent with this hypothesis, the extent of microglial activation estimated by HLA-DR immunostaining was reported to be closely correlated with the amount of αS deposited in the brain of PD patients (Croisier, Moran, Dexter, Pearce, & Graeber, 2005) .
Here, our specific aim was to evaluate the pro-inflammatory potential of amyloid fibrils of αS, using glutamate release as a marker of the activation state of these cells. Our interest in this marker lies in the fact that activated microglial cells can release glutamate in amounts that have the propensity to promote excitotoxic stress (Mesci et al., 2015) , a glutamate-receptor-mediated process thought to contribute to PD neurodegeneration (Ambrosi, Cerri, & Blandini, 2014; Wallace et al., 2007) .
So, we established a model system of pure microglial cells in culture and used these cultures to evaluate the impact of αS aggregates (αSa) on glutamate release. We found that αSa had a strong stimulatory effect on glutamate release through a sequence of signaling events that ultimately lead to activation of the cystine/glutamate antiporter system Xc − . Most interestingly, the stimulatory effect of αSa on glutamate release was totally suppressed by the neurotransmitter DA which operated through activation of D 1 DA receptors. 
| MATERIALS AND METHODS

| Pharmacological and cell culture reagents
| Primary antibodies
| Coating procedures
When needed, bottom surface areas of culture vessels were covered with 1 mg/ml polyethyleimine (PEI; weight average molar mass 750,000; #P3143, Sigma Aldrich) diluted in a pH 8.3 borate buffer solution (40 mM) (Rousseau, Michel, & Hirsch, 2013) . After at least 1-2 hr at 37 C, culture vessels were washed four times with Dulbecco's phosphate buffered saline medium (PBS) before application of culture medium and cell seeding. We also used laminin (#11243217001, Sigma Aldrich) diluted in PBS as a coating for experiments made with astrocytes.
| Microglial cell cultures
Microglial cells were isolated from the brain of newborn mouse pups (postnatal day 1) using a simple culture procedure that allows spontaneous and selective isolation of these cells in bulk quantities . Briefly, the isolation was performed by plating mechanically dissociated brain cells in PEI-coated Corning T-75 flasks (Sigma Aldrich) containing DMEM supplemented with 10% FCS and antibiotics. After a single medium change for removing cellular debris at day 2 in vitro, the cultures were kept as such for 14-16 more days until completion of microglial cell isolation. When needed, purified microglial cell cultures were maintained longer in culture flasks by completing the cultivation medium with a small aliquot of fresh medium. To produce subcultures, microglial cells were recovered by trypsin proteolysis using an EDTA (2 mM)-trypsin (0.05%) solution and seeded in PEI-coated 48 multiwell plates at a density of about 100,000 cells. The cultures were then maintained in N5 medium, a cerebrospinal fluid-like medium (Kaufman & Barrett, 1983) . This medium was supplemented with 5% horse serum, 0.5% FCS, 5 mM glucose and 100 μM glycine. Cultures were maintained at 37 C under a humidified atmosphere of 95% air and 5% CO 2 . These cultures were virtually free of astrocytes.
| Astrocyte cultures
To produce cultures enriched in astrocytes, we used a protocol of isolation that differed to that described previously for microglial cells, in that the coating was laminin and the culture medium DMEM/F-12 nutrient mixture supplemented with 10% FCS and antibiotics. The growth of these cultures was stopped after 2 weeks, that is, at a stage where >90% of the cultured cells are astrocytes.
To produce subcultures, adherent cells were recovered by trypsin proteolysis as described previously for microglial cells and seeded at a density of about 100,000 cells in Nunc 48 multiwell plates coated with laminin and filled with N5 medium supplemented with serum.
Experiments of stimulation were performed in confluent astrocyte cultures.
| Purification of recombinant αS
Human αS was expressed in Escherichia coli using the pT7-7 expression plasmid and purified as described (González-Lizárraga et al., 2017; Hoyer et al., 2002; Kaylor et al., 2005 uranyl acetate in water for 5 min at room temperature, the preparations were examined using a Hitachi HT7700 electron microscope (Elexience, Verrières-le-Buisson) operating at 70 kV as described (Ndour et al., 2017 ). 
| Protein detection by immunofluorescence
| Counts of DAPI + nuclei
Numbers of DAPI + nuclei were estimated by automated counting using an Arrayscan XTi workstation equipped with the HCS Studio 2.0
Software (ThermoScientific, Courtaboeuf, France).
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| Western immunoblotting
Microglial cells were first pretreated with pharmacological reagents and 2 hr later with αSa. After 30 min (for p-AKT) and 24 hr (for total AKT or GADPH) of αSa stimulation, cells were processed using a protocol described earlier by Santa-Cecília et al. (2016) . Briefly, adherent cells were treated with a M-PER buffer (#78501; Invitrogen) containing a protease and phosphatase inhibitor cocktail (#78440; Invitrogen) and aliquots of lysates were recovered for protein quantification with a Nanodrop 8000 Spectrophotometer (Thermofischer Scientific).
Equal amounts of protein lysates were then resolved on a 10% poly- 
| Glutamate assay
Glutamate was assayed using the Amplex Red Glutamic Acid/Glutamate Oxidase Kit (#A12221; Invitrogen) according to the manufacturer's instructions. The quantification was carried out with 25 μl of culture medium and the fluorescent reaction product resulting from glutamic acid oxidation was quantified using a SpectraMax M4 microplate reader (Molecular Devices, Sunnyvale, CA).
| Measurement of [ 14 C]-cystine uptake
Cystine transport was measured based on a protocol described by Tomi, Hosoya, Takanaga, Ohtsuki, and Terasaki (2002) . Briefly, microglial cells exposed to test treatments for 2 hr at 37 C were then incu- The radioactivity accumulated by cultured cells was released by treatment with distilled water and quantified by liquid scintillation counting.
| Quantification of intracellular ROS levels
Intracellular reactive oxygen species (ROS) were assessed using the membrane permeable CellROX Deep Red Reagent (Invitrogen Life Technologies), as described elsewhere .
| Statistical analysis
Experimental values expressed as mean ± SEM were derived from at least two sets of independent experiments. Statistical analyses were performed with the SPSS software for Windows (version 20). All pairwise comparisons were made by one-way ANOVA followed by the Student-Newman-Keuls post hoc test.
3 | RESULTS
| αSa stimulate glutamate release in microglial cell cultures
We measured the impact that a 24-hr treatment with monomeric αS (αSm) (70 μg/ml) or with αSa (15 and 70 μg/ml) had on the release of glutamate in PEI-isolated microglial cell cultures, using LPS (10 ng/ml) as a reference inflammogen (Lu, Yeh, & Ohashi, 2008) . A treatment with 15 μg/ml αSa caused a small but nonsignificant increase in glutamate release. With 70 μg/ml αSa, however, the release of glutamate was robustly and significantly increased (p < .0001 vs. control) (Figure 1a ). The impact of 70 μg/ml αSa on glutamate release was roughly equivalent to that produced by 10 ng/ml LPS (p < .0001
vs. control). Importantly, a treatment of microglial cell cultures with 70 μg/ml αSm did not affect glutamate release, indicating that nonaggregated monomeric forms of αS had no influence on this process.
TEM images shown in Figure 1b confirmed that amyloid fibrils were present in αS shaken samples, only (lower image).
Astroglial cells which are also known to promote inflammatorytype reactions during neurodegeneration (Liddelow & Barres, 2017) , failed to release glutamate in response to αSa (70 μg/ml) ( Figure 1c) . A similar result was found when astrocytes were challenged with LPS (10 ng/ml).
To determine to what extent increases in glutamate release induced by αSa (70 μg/ml) or LPS (10 ng/ml) were related to changes in microglial cell numbers, we counted the number of DAPI + nuclei in cultures receiving or not these treatments ( Figure 1d ). We found that the number of DAPI + nuclei was slightly augmented by about 1.25-fold and 1.15-fold in αSa (70 μg/ml)-and LPS (10 ng/ml)-treated cultures, respectively (p < .001 and .05 vs. control).
We also evaluated the impact of αSa on microglial cells using other inflammation markers. αSa (70 μg/ml) stimulated the release of the prototypical inflammatory cytokine TNF-α with similar efficacy as LPS (10 ng/ml) (p < .001 vs. control) (Figure 1e ). αSa also strongly enhanced the expression of the microglial activation marker Iba-1 in CD11b + cells (Figure 1f ), indicating that the increase in glutamate release induced by the fibrillary forms of the protein was reflecting a more generalized inflammatory state in microglial cells.
| αSa stimulate glutamate release in microglial cells through a receptor-mediated process
We found that αSa were frequently co-localized with the immunofluorescence signal for the cell surface integrin CD11b, when the antibody against human αS was used without permeabilization ( Figure 2a ).
Aggregates were virtually absent in microglial cell bodies in these conditions ( Figure 2a ). Intracellular aggregates of αS remained also scarce after permeabilization (unshown data), suggesting that the intrinsic phagocytocytic activity of microglial cells was reduced in present culture conditions or alternatively that our antibody did not recognize particles that had been phagocytized.
The presence of aggregates close to plasma membranes was an indication that the induction of glutamate release by αSa was possibly mediated by activation of microglial cell membrane receptors. To address this point, microglial cells were exposed to αSa (70 μg/ml) in the presence or not of MAb mTLR2 (2.5 μg/ml), an antagonistic antibody for TLR2 receptors (Chen, Xie, Turkson, & Zhuang, 2015) . In the same setting, we also tested the impact of JNJ (20 μM), a synthetic antagonist for purinergic P2X7 receptors (Letavic et al., 2013) . Figure 2b shows that glutamate release induced by αSa was markedly 3.3 | Glutamate release induced by αSa in microglial cells occurs through activation of the X − c antiporter system Next, we tested the possibility that αSa could stimulate glutamate release by activating the antiporter system Xc − , a membrane protein that imports into the cells the amino acid L-cystine, the oxidized form of cysteine, and exports L-glutamate in a 1:1 ratio (Lewerenz et al., 2013; Soria et al., 2016) . To test this possibility, we studied the impact of the Xc − inhibitor Sulfa (Shukla et al., 2011) on the release of glutamate induced by αSa. Figure 3a shows that the induction of glutamate release by αSa (70 μg/ml; p < .0001 vs. control) was completely antagonized by Sulfa (50 μM; p < .0001 vs. αSa). Note that basal glutamate release was also totally suppressed by Sulfa in the absence of 
| Glutamate release induced by αSa in microglial cells results from a rise in intracellular oxidative stress
We next tested whether activation of the Xc − system and ensuing stimulation of glutamate release were because of a rise of intracellular oxidative stress in microglial cells. For that, we tested the impact of various antioxidants on glutamate release in αSa-treated cultures. p < .0001 vs. αSa; DPI: p < .001 vs. αSa). The cell permeable analog of vitamin E, TROL (10 μM) was found as efficient as APO in the present setting (p < .0001 vs. αSa).
So, to further confirm that oxidative stress was implicated in the stimulatory effects that αSa exert on glutamate release in microglial cells, we measured intracellular ROS production using the membrane permeable fluorogenic probe CellROX Deep Red Reagent (SepulvedaDiaz et al., 2016). As expected ROS production was enhanced by 70 μg/ml αSa (p < .0001 vs. control) in microglial cells (Figure 4b,c) and prevented by APO, DPI, and TROL (APO, DPI, TROL: p < .0001
vs. αSa), that is, treatments reducing glutamate release in αSa-treated cultures.
3.5 | The neurotransmitter dopamine prevents glutamate release induced by αSa in microglial cells through D 1 receptor activation
Next, we were interested in studying whether the neurotransmitter DA had an impact on the release of glutamate induced by αSa in microglial cell cultures. More specifically, we found that DA (10 μM)
totally abolished the stimulatory action of αSa (70 μg/ml) on glutamate release (p < .0001 vs. αSa) (Figure 5a ). Note that DA also suppressed basal glutamate release under control conditions (p < .0001
vs. control).
We wished to further characterize the inhibitory action of DA on glutamate release induced by αSa in microglial cells. For that we tested the impact that specific D 1 and D 2 DA receptor agonists could have on this process. D 1 receptors being most generally coupled to Gs and cAMP production (Beaulieu & Gainetdinov, 2011) , we also tested the impact of the adenylate cyclase activator FK on glutamate release.
LY (2.5 μM), an inhibitor of phosphoinositide 3-kinase (PI3K) was also tested in this experimental context (Figure 5b ). We found that the D 1 DA receptor agonist SKF-81,297 (10 μM) was able to mimic the inhibitory action of DA on glutamate release (p < .0001 vs. αSa) whereas the D 2 agonist ERG (10 μM) failed to do so. We also established that FK (10 μM) led to substantial but only partial reduction of glutamate release in response to αSa exposure (p < .001 vs. αSa), whereas LY (2.5 μM) had a strong inhibitory action under the same conditions (p < .0001 vs. αSa).
This last observation prompted us to study expression levels of p-AKT, the enzymatic product of PI3K, using a Western blotting approach. In particular, we compared conditions in which αSa was applied alone or in the presence of DA, FK, or LY to microglial cell cultures ( Figure 5c ). Quantitative Western blot analysis revealed that the expression of p-AKT was induced by αSa (p < .05 vs. control) and this effect was prevented by either DA (p < .001 vs. αSa) or FK (p < .001
vs. αSa) (Figure 5d ). As expected, LY also robustly inhibited p-AKT expression in microglial cell cultures exposed to αSa (p < .0001 vs. αSa).
| Dopamine prevents glutamate release induced by αSa in microglial cells through an antioxidant effect
We wished to determine whether the reduction in glutamate release produced by DA in αSa-treated microglial cultures was possibly we measured intracellular ROS production in microglial cell cultures exposed to 70 μg/ml αSa in the presence or not of 10 μM DA (Figure 6a,b) . In the same setting, we also tested the impact of the adenylate cyclase activator FK (10 μM) and that of the PI3K inhibitor LY (2.5 μM) on ROS production (Figure 6a,b) . Most notably, we found that the increase in intracellular ROS production induced by αSa was totally abolished by DA (10 μM) (p < .0001 vs. αSa). Note that DA also reduced ROS production below control levels in the absence of αSa (p < .01 vs. control). Interestingly, ROS produced by αSa were also reduced by the PI3K inhibitor LY (2.5 μM) (p < .01 vs. αSa) and the adenylate cyclase activator FK (10 μM) (p < .05 vs. αSa).
Finally, we tested the possibility that DA could prevent αSa-mediated ROS production by inhibiting the expression of NOX2, the NOX isoform that is most abundant in microglia cells (Bedard & Krause, 2007) . For that we measured cellular expression levels of the NOX2 p47phox subunit in cultures exposed to αSa in the presence or not of DA or FK. We also tested the impact of LY in this setting (Figure 6c,d) . We established that p47phox expression was induced in αSa-treated microglial cultures (p < .0001 vs. control) and that this induction was prevented when DA (10 μM) was added concomitantly to the cultures (p < .0001 vs. αSa). Cyclic AMP elevation with FK (10 μM) caused a reduction in the induction of p47phox elicited by αSa (p < .05 vs. αSa). Meanwhile, p47phox returned to basal levels in cultures exposed to αSa in the presence of LY (2.5 μM) (p < .0001 vs. αSa). Overall, these data suggest that DA prevented PI3K-dependent activation of NOX2 by αSa. All these results are summarized in Figure 7 .
| DISCUSSION
Using a model system of post-natal microglial cells in culture, we established that aggregated (but not monomeric) forms of αS had the capacity to robustly stimulate glutamate release through a mechanism requiring concomitant activation of TLR2 and P2X7 receptors and sequential stimulation of the PI3K and NOX enzymes. The Xc -antiporter system appeared to be the final downstream effector for αSa-mediated glutamate release. Interestingly, the effects of αSa on glutamate release were antagonized by the neurotransmitter DA through a mechanism that involves D 1 DA receptors.
| Aggregated but not monomeric forms of αS stimulate glutamate release in microglial cell cultures
The aggregation process of the synaptic protein αS represents one of the key pathological events in PD. It has been suggested that pathological forms of αS that diffuse and propagate in the brain parenchyma (Bernis et al., 2015; Dijkstra et al., 2014 ) may contribute to disease progression by favoring inflammatory-type reactions mediated by microglial cells (Couch et al., 2011) . Here, we wished to evaluate the pro-inflammatory potential of amyloid fibrils of αS, using glutamate release as an activation marker of these cells. Our specific interest for this marker comes from the fact that glutamate has the potential to generate low-level excitotoxic insults (Lavaur et al., 2017 ) that may aggravate neurodegeneration in PD (Ambrosi et al., 2014 ).
Using a model system of purified microglial cell cultures, we established that amyloid fibrils of αS had the capacity to stimulate glutamate release in a concentration-dependent manner. We found that both TNF-α secretion and cellular expression of the microglial activation marker Iba-1 were also robustly enhanced in the same cultures, indicating that the stimulatory effect of αSa on glutamate release reflected a more generalized inflammatory state of microglial cells. This is coherent with previous reports reporting on the strong pro-inflammatory potential of αS fibrillary species (Brück, Wenning, Stefanova, & Fellner, 2016; Wang et al., 2015; Zhang et al., 2005) . More precisely, we showed that 70 μg/ml αSa had an impact on glutamate release that was equivalent to that of 10 ng/ml of LPS, a bacterial cell-wall component that operates as a protypical inflammogen for microglial cells (Barger, Goodwin, Porter, & Beggs, 2007; Sepulveda-Diaz et al., 2016) . Note that in some culture settings, toxic effects of aggregated forms of αS have been reported at much lower concentrations (Kim et al., 2013; Zhang et al., 2005) . Concentrations comparable to those used by us in the present study were, however, required in other paradigms (Bussi et al., 2017; Hoffmann et al., 2016) . We have no definite explanation for such differences, which may be attributable to different culture conditions and various procedures used to generate aggregated species of αS.
At variance to αSa, αSm were totally ineffective in promoting glutamate release in microglial cells in the same experimental setting.
These observations are coherent with reports showing that the inflammatory potential of αS is dependent on the aggregation state of the protein (Hoffmann et al., 2016) . Incidentally, the absence of effect of αSm confirms indirectly that the human recombinant αS that we prepared for this study was free of bacterial contaminants susceptible to induce glutamate release in microglial cells (Barger et al., 2007) .
Another population of glial cells, the astrocytes, are also involved in inflammatory-type reactions during neurodegeneration (Liddelow & Barres, 2017) . Like microglia, astrocytes possess the capacity to release glutamate in physiological and pathological conditions (Montana, Verkhratsky, & Parpura, 2014; Vesce, Rossi, Brambilla, & Volterra, 2007 ). Thus, we tested whether αSa had the potential to stimulate the release of the neurotransmitter when applied to astrocyte cultures. Contrarily to our expectation, we did not observe an increase in glutamate release when astrocytes were challenged with αSa, which means that the stimulatory action of αSa on the release process was rather specific to microglial cells.
Importantly, the capacity of αSa to trigger glutamate release from microglia signifies that the excitotoxic process affecting substantia nigra DA neurons in PD may not simply result from an increased excitatory drive from subthalamic glutamatergic neurons as suggested before (Lavaur et al., 2017; Wallace et al., 2007) but also from a local rise of the neurotransmitter.
| αSa-mediated glutamate release in microglial cells is mediated by activation of membrane receptors
The presence of αSa closely apposed to plasma membranes is coherent with the know ability of amyloid-like structures to bind to cell membrane components (Shrivastava, Aperia, Melki, & Triller, 2017) .
This was also an indication that the stimulatory action of protein aggregates on microglial glutamate release may result from an interaction with cell membrane signal transducing receptors. Supporting this view, we found that glutamate release induced by αS was largely reduced in the presence of an antagonistic antibody for TLR2 (Chen et al., 2015) , a receptor subtype that is presumably involved in PDrelated brain inflammation (Kim, Lee, Masliah, & Lee, 2016; Watson et al., 2012) . Our result is in agreement with data reported by Gustot et al. (2015) showing that αS amyloid fibrils can trigger inflammatorytype reactions through a TLR-2-dependent mechanism. Kim et al. (2013) have shown, however, that αS oligomers spontaneously secreted by a neuroblastoma cell line had the potential to activate TLR-2 in microglial cells whereas fibrils produced from recombinant αS were unable to do so. Such discrepancies may be because of structural heterogeneity of αS oligomeric and fibrillary species in between studies (Bousset et al., 2013 : Kumar, Singh, Kumari, & Udgaonkar, 2017 . Glutamate release induced by αSa was also significantly curtailed by JNJ, a synthetic antagonist for purinergic P2X7 receptors (Letavic et al., 2013) , which is reminiscent to previous studies showing that oligomeric forms of αS bind directly to this receptor subtype . The implication of P2X7 receptors in the effects of αS fibrils has, however, not been reported previously.
Overall, these observations suggest that in our model system, both TLR2 and P2X7 receptors contributed to αSa-mediated glutamate release by microglial cells. Accordingly, a combined treatment with the TLR2 antagonistic antibody and the P2X7 antagonist JNJ was required to completely suppress the stimulatory action that αSa exert on glutamate release. Still in accord with our present finding, we found that glutamate release was stimulated by selective agonists of each receptor subtype, Pam3CSK4 and BzATP and that this stimulatory effect was further enhanced by a treatment combining the two agonist compounds.
4.3 | αSa-mediated glutamate release in microglial cells results from an increase in intracellular oxidative stress
Next, we aimed to better understand the nature of the mechanisms that control glutamate release in microglial cells stimulated by αSa.
Experiments showing that DPI and APO, two inhibitors of the NOX superoxide producing enzyme were able to suppress glutamate release induced by αSa, suggested that ROS contributed actively to the release process. TROL, a compound that inhibits hydroxyl radicalmediated lipid peroxidation was as efficient as the NOX inhibitors to prevent glutamate release, indicating that superoxide-dependent hydroxyl radicals and/or lipid peroxyl radicals (Franzoni et al., 2006) operated as key mediators in this process. Quantitative detection of ROS with the membrane permeable fluorogenic probe CellROX confirmed that DPI, APO and TROL were all highly effective in preventing intracellular ROS production in microglia exposed to αSa. Note that glutamate release was also reported to be stimulated through NOX activation in microglial cells exposed to the bacterial inflammogen LPS (Barger et al., 2007) which indicates that intracellular events contributing to glutamate release in αSa-and LPS-treated microglial cells share comonalities.
In addition to that, we found that inhibition of PI3K with LY prevented the induction of ROS by αSa which is coherent with reports showing that both TLR2 (Lu et al., 2011) and P2X7 ligands signal through PI3K activation . This also indicated that a PI3K-dependent mechanism controlled NOX activation in the present setting. Coherent with this view, the stimulation of microglial cells by αSa increased the immunofluorescent signal of p47phox, a subunit of NOX2, the NOX isoform that is predominant in microglial cells (Bedard & Krause, 2007) . As expected this effect was totally reversed by PI3K inhibition, which is coherent with a previous report showing that PI3K controls NOX2 activation in microglial cells exposed to αS oligomers . Still consistent with our results, Hou et al. (2018) reported that p47phox was robustly activated by αSa in microglial cultures. However, this effect which required activation of the CD11b integrin appeared not dependent on TLR-2 signaling.
4.4 | The Xc -cystine/glutamate antiporter system operates as downstream effector for αSa-mediated glutamate release
Note that we also observed that inhibition of αSa-mediated glutamate release by PI3K blockade was reproduced by Sulfa, an antiinflammatory drug, which operates as inhibitor of the Xc -cystine/glutamate antiporter system (Shukla et al., 2011) . This suggested that Xc -was possibly the final downstream effector for glutamate release stimulation by αSa in microglial cells. Comforting this view, the increase in glutamate release induced by αSa was accompanied by a concomitant rise in the uptake of L-cystine, the oxidized dimer of cysteine, a critical precursor for synthesis of the antioxidant defense tripeptide glutathione (Lu et al., 2009) . Cystine uptake appeared also largely antagonized by Sulfa, confirming that the aminoacid was accumulated through the Xc -antiporter. Given that several antioxidants also prevented glutamate release induced by αSa, one may assume that the increased activity of the antiporter was closely related to the induction of oxidative stress by aggregated forms of the protein.
4.5 | The neurotransmitter dopamine prevents αSa-mediated glutamate release through an antioxidant effect
The loss of DA neurons and the ensuing depletion in brain DA is another key pathological feature of PD (Rodriguez-Oroz et al.,
2009). Thus, we were interested in determining whether a deficit in DA could facilitate glutamate release induction by αSa.
Consistent with this view, we found that DA was potently inhibiting glutamate release in cultures that were challenged with αSa.
This result is reminiscent of previous observations showing that DA can reduce some of the inflammatory responses in microglia (Färber, Pannasch, & Kettenmann, 2005) and also in bone marrow-derived macrophages (Yan et al., 2015) . The inhibitory effect of DA was entirely mimicked by a selective D 1 DA receptor agonist SKF-81,297 whereas ERG, an agonist at D 2 receptors failed to do so, indicating that DA effects resulted most probably from D 1 receptor activation. So, the possibility that DA could reduce the immunotoxicity of αS fibrils indirectly by forming complexes with them (Béraud et al., 2013) seemed rather unlikely.
Note that DA reduced PI3K activation and ROS production in αSa-treated microglial cultures, which signifies that DA counteracted glutamate release stimulation by inhibiting PI3K-dependent signaling.
To mimic the effects of D 1 receptor activation in the present setting, we used the adenylate cyclase activator FK because this DA receptor subtype is coupled to cAMP production (Beaulieu & Gainetdinov, 2011) . Even if being quite effective in reducing PI3K activation, 
